AbbVie 2012 Annual Report Download - page 128

OWNERSHIP OF SECURITIES
Security Ownership of Executive Officers and Directors
The table below reflects the number of shares of AbbVie common stock beneficially owned as of
January 31, 2013, by each director, the chief executive officer, the chief financial officer, and the three
other most highly paid executive officers (the ‘‘named executive officers’’), and by all directors and
executive officers of AbbVie as a group. It also reflects the number of stock equivalent units and
restricted stock units held by non-employee directors under the AbbVie Non-Employee Directors’ Fee
Plan.
Stock Options
Exercisable
Shares within 60 days Stock
Beneficially of January 31, Equivalent
Name Owned(1)(2)(3) 2013 Units
R. A. Gonzalez ................................... 49,432 54,133 0
R. J. Alpern ..................................... 8,559 0 0
R. S. Austin ..................................... 23,066 0 0
W. H.L. Burnside ................................. 0 0 0
E. M. Liddy ..................................... 5,121 0 0
E. J. Rapp ...................................... 0 0 0
R. S. Roberts .................................... 20,000 0 0
G. F. Tilton ...................................... 19,556 0 0
F. H. Waddell .................................... 0 0 0
L. J. Schumacher ................................. 207,785 214,198 0
W. J. Chase ...................................... 90,250 98,175 0
C. Alban ....................................... 153,206 191,949 0
J. M. Leonard .................................... 128,771 251,900 0
All directors and executive officers as a
group (15 persons)(4)(5) ............................ 180,941 855,446 0
(1) The table includes shares held in the executive officers’ accounts in the AbbVie Savings Plan as
follows: J. M. Leonard, 6,473; and all executive officers as a group, 8,117. Each officer has shared
voting power and sole investment power with respect to the shares held in his or her account.
(2) The table includes 20,749 restricted stock units held by the executive officers as a group. The
officers do not have sole voting and investment power until the restrictions lapse. The table also
includes restricted stock units held by the non-employee directors. The directors’ units are payable
in stock upon termination, retirement from the board, death, or a change in control of AbbVie as
follows: R. J. Alpern, 8,559; R. S. Austin, 16,222; E. M. Liddy, 3,986; and G. F. Tilton, 12,206.
(3) The table includes shared voting and/or investment power over shares as follows: G. F. Tilton, 350;
W. J. Chase, 12,329; C. Alban, 40,442; and all directors and executive officers as a group, 41,403.
(4) Certain executive officers of AbbVie are fiduciaries of employee benefit trusts maintained by
AbbVie. As such, they have shared voting and/or investment power with respect to the common
shares held by those trusts. The table does not include the shares held by the trusts.
(5) Excluding the shared voting and/or investment power over the shares held by the trusts described
in footnote(4), the directors and executive officers as a group together own less than one percent
of the outstanding shares of AbbVie.
14